Title:
METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO Fc&gammad RECEPTOR IIIa
Document Type and Number:
WIPO Patent Application WO/2003/085119
Kind Code:
A1
Abstract:
A method of enhancing the activity of an antibody of binding to Fc&gammad receptor IIIa; a method of enhancing the antibody-dependent cytotoxic activity of an antibody composition; a method of detecting the ratio of sugar chains having no fucose bonded to N-acetylglucosamine at the sugar chain reducing end among total N-glycoside bond-type complex sugar chains binding to the Fc region contained in an antibody composition; a method of detecting an antibody-dependent cytotoxic activity; an Fc-fused protein composition produced with the use of cells having tolerance to a lectin recognizing a sugar chain structure in which an &agr -bond is formed between the 6-position of N-acetylglucosamine at the reducing end of an N-glycoside bond-type complex sugar chain and the 1-position of fucose; and a process for producing the same.
More Like This:
Inventors:
NAKAMURA KAZUYASU (US)
SHITARA KENYA (JP)
SHITARA KENYA (JP)
Application Number:
PCT/JP2003/004504
Publication Date:
October 16, 2003
Filing Date:
April 09, 2003
Export Citation:
Assignee:
KYOWA HAKKO KOGYO KK (JP)
NAKAMURA KAZUYASU (US)
SHITARA KENYA (JP)
NAKAMURA KAZUYASU (US)
SHITARA KENYA (JP)
International Classes:
A61K39/395; A61P9/00; A61P29/00; A61P31/04; A61P31/12; A61P31/14; A61P35/00; A61P37/02; A61P37/04; A61P37/08; A61P43/00; C07K16/22; C07K16/28; C07K16/30; C12P21/02; C12P21/08; (IPC1-7): C12P21/08; C12N15/09; C12N5/10; C07K16/18; G01N33/50; C07K16/46
Domestic Patent References:
| WO2000061739A1 | 2000-10-19 | |||
| WO1997027303A1 | 1997-07-31 | |||
| WO2002031140A1 | 2002-04-18 |
Other References:
RIPKA J. ET AL.: "Two Chinese hamster ovary glycosylation mutants affected in the conversion of GDP mannose to GDP-fucose", ARCH. BIOCHEM. BIOPHYS., vol. 249, no. 2, 1986, pages 533 - 545, XP002971006
SHITARA K. ET AL.: "A new vector for the high level expression of chimeric antibodies in myeloma cells", J. IMMUNOL. METHODS, vol. 167, no. 1-2, 1994, pages 271 - 278, XP002911931
DAVIES J. ET AL.: "Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII", BIOTECHNOL. BIOENG., vol. 74, no. 4, 2001, pages 288 - 294, XP002964541
HACKETT J. JR. ET AL.: "Recombinant mouse-human chimeric antibodies as calibrators in immunoassays that measure antibodies to toxoplasma gondii", J. CLIN. MICROBIOL., vol. 36, no. 5, 1998, pages 1277 - 1284, XP002971007
ELBASHIR S.M. ET AL.: "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells", NATURE, vol. 411, no. 6836, 2001, pages 494 - 498, XP002206451
SHIELDS R.L. ET AL.: "High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII and FcRn and design of IgG1 variants with improced binding to the Fc gamma R", J. BIOL. CHEM., vol. 276, no. 9, 2001, pages 6591 - 6604, XP002971008
SHIELDS R.L. ET AL.: "Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fc gamma RIII and antibody-dependent cellular toxicity", J. BIOL. CHEM., vol. 277, no. 30, July 2002 (2002-07-01), pages 26733 - 26740, XP002964542
SINKAWA T. ET AL.: "The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity", J. BIOL. CHEM., vol. 278, no. 5, 2003, pages 3466 - 3473, XP002965857
See also references of EP 1498491A4
SHITARA K. ET AL.: "A new vector for the high level expression of chimeric antibodies in myeloma cells", J. IMMUNOL. METHODS, vol. 167, no. 1-2, 1994, pages 271 - 278, XP002911931
DAVIES J. ET AL.: "Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII", BIOTECHNOL. BIOENG., vol. 74, no. 4, 2001, pages 288 - 294, XP002964541
HACKETT J. JR. ET AL.: "Recombinant mouse-human chimeric antibodies as calibrators in immunoassays that measure antibodies to toxoplasma gondii", J. CLIN. MICROBIOL., vol. 36, no. 5, 1998, pages 1277 - 1284, XP002971007
ELBASHIR S.M. ET AL.: "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells", NATURE, vol. 411, no. 6836, 2001, pages 494 - 498, XP002206451
SHIELDS R.L. ET AL.: "High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII and FcRn and design of IgG1 variants with improced binding to the Fc gamma R", J. BIOL. CHEM., vol. 276, no. 9, 2001, pages 6591 - 6604, XP002971008
SHIELDS R.L. ET AL.: "Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fc gamma RIII and antibody-dependent cellular toxicity", J. BIOL. CHEM., vol. 277, no. 30, July 2002 (2002-07-01), pages 26733 - 26740, XP002964542
SINKAWA T. ET AL.: "The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity", J. BIOL. CHEM., vol. 278, no. 5, 2003, pages 3466 - 3473, XP002965857
See also references of EP 1498491A4
Attorney, Agent or Firm:
Oguri, Shohei (28th Floor ARK Mori Building, 12-32, Akasaka 1-chom, Minato-ku Tokyo, JP)
Download PDF: